Trials / Completed
CompletedNCT04701580
Synaptic Density and Progression of Huntington's Disease.
Longitudinal Measurement of Synaptic Density to Monitor Progression of Huntington's Disease.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with HD. DESIGN: The investigators will include 20 HD mutations carriers and 15 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FDG PET-MR at baseline and after 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 11C-UCB-J PET-CT | Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J. |
| DIAGNOSTIC_TEST | 18F-FDG PET-MR | Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously. |
Timeline
- Start date
- 2020-01-14
- Primary completion
- 2022-10-05
- Completion
- 2022-10-05
- First posted
- 2021-01-08
- Last updated
- 2022-11-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04701580. Inclusion in this directory is not an endorsement.